The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health
Open accessAbstract
Mental illnesses, such as bipolar disorder, attention-deficit/hyperactivity disorder, depression and schizophrenia are a major public health concern worldwide. Several pharmacologic agents acting on monoamine neurotransmission are used for the management of these disorders. However, there is still little understanding of the ultimate molecular mechanisms responsible for the therapeutic effects of these drugs or their relations with disease etiology. Here I provide an overview of recent advances on the involvement of the signalling molecules Akt and glycogen synthase kinase-3 (GSK3) in the regulation of behaviour by the monoamine neurotransmitters dopamine (DA) and serotonin (5-HT). I examine the possible participation of these signalling molecules to the effects of antidepressants, lithium and antipsychotics, as well as their possible contribution to mental disorders. Regulation of Akt and GSK3 may constitute an important signalling hub in the subcellular integration of 5-HT and DA neurotransmission. It may also provide a link between the action of these neurotransmitters and gene products, like disrupted in schizophrenia 1 (DISC1) and neuregulin (NRG), that are associated with increased risk for mental disorders. However, changes in Akt and GSK3 signalling are not restricted to a single disorder, and their contribution to specific behavioural symptoms or therapeutic effects may be modulated by broader changes in biologic contexts or signalling landscapes. Understanding these interactions may provide a better understanding of mental illnesses, leading to better efficacy of new therapeutic approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., & Hemmings, B. A. (1995) · Nature · doi:10.1038/378785a0 · Cited by 5,244
The physiology, signaling, and pharmacology of dopamine receptors
Beaulieu, J.-M., & Gainetdinov, R. R. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002642 · Cited by 2,763
Self-citationThe Genetic Landscape of a Cell
Costanzo, M., Baryshnikova, A., Bellay, J., Kim, Y., Spear, E. D., Sevier, C. S., Ding, H., Koh, J. L. Y., Toufighi, K., Mostafavi, S., et al. (2010) · Science · doi:10.1126/science.1180823 · Cited by 2,162
Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells
Stambolic, V., Ruel, L., & Woodgett, J. R. (1996) · Current Biology · doi:10.1016/s0960-9822(02)70790-2 · Cited by 1,321
Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
Mice with Reduced NMDA Receptor Expression Display Behaviors Related to Schizophrenia
Mohn, A. R., Gainetdinov, R. R., Caron, M. G., & Koller, B. H. (1999) · Cell · doi:10.1016/s0092-8674(00)81972-8 · Cited by 1,075
Neural development, cell-cell signaling, and the “two-hit” hypothesis of schizophrenia
Maynard, T. M., Sikich, L., Lieberman, J. A., & LaMantia, A.-S. (2001) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006887 · Cited by 383
Prickaerts, J., Moechars, D., Cryns, K., Lenaerts, I., van Craenendonck, H., Goris, I., Daneels, G., Bouwknecht, J. A., & Steckler, T. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.5216-05.2006 · Cited by 341
In Vivo Regulation of Glycogen Synthase Kinase-3β (GSK3β) by Serotonergic Activity in Mouse Brain
Li, X., Zhu, W., Roh, M.-S., Friedman, A. B., Rosborough, K., & Jope, R. S. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300439 · Cited by 300
Is Glycogen Synthase Kinase-3 a Central Modulator in Mood Regulation?
Li, X., & Jope, R. S. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.105 · Cited by 294
Cited by
The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., et al. (2018) · Brain · doi:10.1093/brain/awy132 · Cited by 1,918
Dopamine receptors –IUPHAR R eview 13
Beaulieu, J., Espinoza, S., & Gainetdinov, R. R. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12906 · Cited by 521
Self-citationAnimal models of bipolar mania: The past, present and future
Logan, R. W., & McClung, C. A. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2015.08.041 · Cited by 136
GSK3β: a master player in depressive disorder pathogenesis and treatment responsiveness
Duda, P., Hajka, D., Wójcicka, O., Rakus, D., & Gizak, A. (2020) · Cells · doi:10.3390/cells9030727 · Cited by 84
Lago, S. G., Tomasik, J., van Rees, G. F., Ramsey, J. M., Haenisch, F., Cooper, J. D., Broek, J. A., Suarez-Pinilla, P., Ruland, T., Auyeug, B., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0123-4 · Cited by 30
Metadata
- Authors
- Beaulieu, J.-M.
- Venue
- Journal of Psychiatry and Neuroscience
- Publisher
- Canadian Science Publishing
- Published
- 2012-01
- Volume
- 37
- Issue
- 1
- Pages
- 7-16
- ISSN
- 1180-4882 (ISSN-L)
- OpenAlex
- W2152248242
- Cited by
- 238
- References
- 14
- FWCI
- 13.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health. https://app.cochat.ai/papers/10.1503/jpn.110011
- The paper
- Beaulieu, J.-M. (2012). A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health. Journal of Psychiatry and Neuroscience. https://doi.org/10.1503/jpn.110011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
